HC Wainwright set a $11.00 target price on Asterias Biotherapeutics (NYSEAMERICAN:AST) in a research note released on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on AST. Zacks Investment Research raised Asterias Biotherapeutics from a hold rating to a buy rating and set a $1.50 price target for the company in a research report on Tuesday, July 10th. B. Riley set a $6.00 price target on Asterias Biotherapeutics and gave the stock a buy rating in a research report on Friday, August 3rd. Finally, Raymond James downgraded Asterias Biotherapeutics from an outperform rating to a market perform rating in a research report on Friday, August 10th.

NYSEAMERICAN:AST opened at $1.35 on Thursday. Asterias Biotherapeutics has a twelve month low of $1.20 and a twelve month high of $3.74.

Several institutional investors have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in shares of Asterias Biotherapeutics during the 2nd quarter worth approximately $663,000. Creative Planning raised its stake in shares of Asterias Biotherapeutics by 50.0% during the 2nd quarter. Creative Planning now owns 180,313 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 60,100 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Asterias Biotherapeutics during the 2nd quarter worth approximately $194,000. Renaissance Technologies LLC bought a new stake in shares of Asterias Biotherapeutics during the 2nd quarter worth approximately $142,000. Finally, LMR Partners LLP bought a new stake in shares of Asterias Biotherapeutics during the 2nd quarter worth approximately $110,000.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.